TrialOncotarget2015

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.

Mirko Marabese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.